Genmab — Januar 2017
-
Tror ikke det bliver denne gang kommer ned i 1200 igen, men så må vi bare på den igen
der skal meget mere til før vi nærmer os de postive analytiker og os her i Genmab chatten, men skuffet kan man ikke være som Genmab aktionær over de sidste 3 år men dagens tal er vel der hvor kursen skal være måske lidt over men okay God aften........ -
Analytiker: Gode Darzalex-takter forude for Genmab
Johnson & Johnsons lancering af kræftmidlet i Europa er tempofyldt, og den store iver for at øge salget kommer Genmab til gode, lyder det fra aktieanalytiker.
(medwatch.dk)
-
"Virker det i solide tumorer kan man lægge op til 6 mia. dollar oveni," siger Claus Henrik Johansen, senior porteføljeforvalter i Danske Bank." http://borsen.dk/nyheder/virksomheder/artikel/1/338807/danske_bank_nu_aendres_historien_i_genmab.html
-
Njah, Novod har talt om min 5 mia, men ikke blue-sky mig bekendt "Based on our JnJ meeting, we believe that Darzalex could be positioned as one of the
backbone drugs in the company's immuno-oncology strategy and solid tumour potential for Darzalex could
be game-changing; potentially USD 5bn or more. This is not yet reflected in our Genmab valuation. The
first solid tumour data will likely come out in early 2018."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind